Custom small-molecule synthesis
Multi-step organic synthesis from milligram discovery batches through kilogram pilot quantities. We support heterocycles, chiral centers, organometallics and late-stage functionalization with full analytical packages at each handoff.
mg–kg
typical scale bands
1–15
steps supported
Chiral
resolution & asymmetric routes
LC-MS
every batch release
What we synthesize
Custom synthesis covers novelty-building chemistry: kinase hinge binders, PROTAC warheads, lipid chains, boronics, and building blocks that are not yet in catalog form. Projects often start from a literature route or a retrosynthesis exercise and converge on a scalable, impurity-controlled path.
We work in research-grade and GMP-ready documentation modes. For discovery, emphasis is on speed, structure confirmation, and purity suitable for in vitro work. For development partners, we align intermediates with QbD talking points and track genotoxic impurity flags early.
Project flow
Scope and route review
You share target structure, quantity, timeline, and any IP or starting-material constraints. We propose one or more synthetic sequences with indicative step yields and key risks (chromatography, cryogenics, metals).
Feasibility and first lots
Medicinal chemistry quantities with full ID (NMR, HRMS, IR as needed) and HPLC purity. Tough steps may be run in parallel to de-risk before you commit to scale.
Analytical lock and documentation
Method development for assay and impurities, specification draft, and stability-enabling crystallization or salt form where appropriate.
Scale-up handoff
Tech package for internal or CMO transfer, or continuation into process development and HPAPI containment if potency demands it.
Deliverables
- Target compound with stated quantity and purity
- Certificate of analysis: appearance, purity (HPLC), identity (NMR/MS), residual solvents, water (KF) where relevant
- Optional interim and side-product inventory for SAR
- Electronic batch records for GMP-track projects
- Route summary and known impurity map for CMC discussions
Indicative release criteria (research grade)
Final specs are project-specific. Ranges below reflect common discovery and preclinical expectations.
Purity (HPLC)
≥ 95–99%
Higher bands on request
Identity
¹H NMR + HRMS
13C, IR, XRPD for APIs
Residual solvents
ICH Q3C
Per class limits
Water
KF
When hygroscopic or salt form
Enantiomeric excess
Chiral SFC/HPLC
When chiral center is critical
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Frequently asked questions
There is no fixed MOQ. Milligram feasibility is common for novel scaffolds; gram and kilogram bands are quoted per route and equipment fit.
Related
Process Development & Scale-up
Route scouting, reaction optimization, crystallization design, and tech transfer packages that turn a workable lab sequence into a reproducible plant-ready process—without rediscovering impurities at every scale tier.
View detailsAPIs & Intermediates
Drug substance and late-stage intermediates manufactured under scalable, documented processes—bridging custom synthesis efforts to clinical and commercial demand with coherent specifications and supply continuity.
View detailsHigh-Potency APIs (HPAPI)
Contained synthesis, isolation, and packaging of potent compounds classified by occupational exposure band (OEB). Programs include cytotoxic warheads, hormone modulators, and other APIs where µg/m³ air quality targets drive facility design.
View detailsPROTACs & Linkers
Heterobifunctional degraders and building blocks: warheads, E3 recruiter ligands, and configurable linkers (PEG, alkyl, triazole) supplied with analytics suited to medchem and CMC teams pursuing targeted protein degradation.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.